In an in-vitro study published in the journal Frontiers in Pharmacology in 2025, the effects of the active ingredient Menthacarin® on the composition of the human intestinal flora and the production of short-chain fatty acids (SCFA) were investigated. It was found that Menthacarin® significantly altered the composition of the microbiota at both phylum and genus level. These effects may contribute to the clinical benefits that may result from the use of Menthacarin® in functional gastrointestinal disorders.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- H. pylori infection: current study data
Fewer gastric carcinomas and peptic ulcers after eradication
- From symptom to diagnosis
Pneumology – tracheal and bronchial calcifications
- Tinea capitis: Current Guidelines and Recommendations
What should be kept in mind when treating adult patients?
- Geriatric patients
Micronutrient Intake in Older Adults
- Crohn's disease: focus on long-term results
“Top-down” approach or classic step therapy?
- SwissDiab Study: New Analysis Published
How are diabetes complications associated with quality of life?
- Pre-acclimatization on Mount Everest
Exploring the physiological limits
- Viloxazine for ADHD